Showing results (71-80 of 301) with videos related to

Sort By:
Pageof 31
Mabs|December 9, 2014
Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cellsChien-Hsing Chang, Yang Wang, Pankaj Gupta, et al.
Autoimmunity Reviews|July 28, 2015
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosusThomas Dörner, Anthony Shock, David M Goldenberg, et al.
BMC Cancer|January 5, 2007
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancersRosalyn D Blumenthal, Evelyn Leon, Hans J Hansen, et al.
Molecular Cancer Therapeutics|April 7, 2011
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft modelsRobert M Sharkey, Habibe Karacay, Serengulam V Govindan, et al.
Cancer|January 30, 2002
Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazineRhona Stein, Susan Chen, Linda Reed, et al.
Blood|July 15, 2010
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Molecular Cancer Therapeutics|November 1, 2011
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignanciesRobert M Sharkey, Serengulam V Govindan, Thomas M Cardillo, et al.
International Journal of Cancer|November 26, 2003
An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expressionRosalyn D Blumenthal, Evelyn Leone, David M Goldenberg, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodiesRobert M Sharkey, Edmund A Rossi, Chien-Hsing Chang, et al.
Anti-Cancer Drugs|April 7, 2007
Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell linesJack D Burton, Mary E Castillo, David M Goldenberg, et al.
Pageof 31